BSEM — Biostem Technologies Income Statement
0.000.00%
Last trade - 00:00
- $123.01m
- $128.92m
- $4.34m
- 17
- 22
- 90
- 38
2015 December 31st | R2016 December 31st | 2017 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PRESS | ARS | ARS | ARS | ARS |
Standards: | — | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.152 | 0.616 | 0.329 | 2.52 | 4.34 |
Cost of Revenue | |||||
Gross Profit | 0.085 | 0.222 | 0.179 | 1.25 | 2.82 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.51 | 3.74 | 5.16 | 4.36 | 5.14 |
Operating Profit | -2.36 | -3.13 | -4.83 | -1.84 | -0.802 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.38 | -3.2 | -4.86 | -2.37 | -1.41 |
Net Income After Taxes | -2.38 | -3.2 | -4.86 | -2.37 | -1.41 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2.38 | -3.2 | -4.84 | -2.39 | -1.37 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.38 | -3.2 | -4.84 | -2.39 | -1.37 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.05 | -0.949 | -1.15 | -0.257 | -0.215 |